Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Liraglutide and Semaglutide Market

Liraglutide and Semaglutide Market Share

Report ID: GMI5886
Published Date: May 2023
Report Format: PDF

Download Free Sample

Liraglutide and Semaglutide Market Share

Major market players operating in the liraglutide and semaglutide market include

Novo Nordisk A/S
HEC Pharma Co
Shenzhen JYMed Technology Co. Ltd.
Bachem Holding AG

These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition. Also, kindly note that the company profile section include both companies that have commercial drug available in market as well as those that are into clinical phase development.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of liraglutide and semaglutide accounted for over USD 14 billion in 2022 and is estimated to cross USD 41 billion by 2032, on account of increasing prevalence diabetes and rising awareness regarding obesity, as the products are used primarily in the treatment of type 2 diabetes and obesity.

The type 2 diabetes mellitus segment is expected to grow at a 11.4% CAGR during 2023 and 2032, owing to product ability to effectively control blood sugar levels by stimulating insulin release and reducing the production of glucagon.

North America accounted for over 71% of the market share in 2022 and is anticipated to grow at considerable rate through 2032, backed by increasing occurrence of diabetes and rising awareness regarding the importance of disease management.

Novo Nordisk A/S, HEC Pharma Co., Shenzhen JYMed Technology Co. Ltd., Bachem Holding AG among others.